Skip to main content

Advertisement

SpringerLink
Log in

Jug-PLGA-NPs, a New Form of Juglone with Enhanced Efficiency and Reduced Toxicity on Melanoma

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To verrify the anti-tumor efficacy and toxicity between juglone (Jug) and Jug-loaded PLGA nanoparticles (Jug-PLGA-NPs).

Methods

Jug-PLGA-NPs were prepared by ultrasonic emulsification. The anti-tumor activity of Jug (2, 3, 4 µg/mL) and Jug-PLGA-NPs (Jug: 2, 3, 4 µg/mL) in vitro was measured by MTT assay and cell apoptosis analysis. The distribution, anti-tumor effect and biological safety in vivo was evaluated on A375 nude mice.

Results

With the advantage of good penetration and targeting properties, Jug-PLGA-NPs significantly inhibited proliferation and migration of melanoma cells both in vitro and in vivo (P<0.05 or P<0.01) with acceptable biocompatibility.

Conclusions

Jug can inhibit the growth of melanoma but is highly toxic. With the advantage of sustained release, tumor targeting, anti-tumor activity and acceptable biological safety, Jug-PLGA-NPs provide a new pharmaceutical form for future application of Jug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

    Article  Google Scholar 

  2. Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, et al. Resistance to molecularly targeted therapies in melanoma. Cancers (Basel) 2021;13:1115.

    Article  CAS  Google Scholar 

  3. Hoffman RM, Bouvet M. Imaging the microenvironment of pancreatic cancer patient-derived orthotopic xenografts (PDOX) growing in transgenic nude mice expressing GFP, RFP, or CFP. Cancer Lett 2016;380:349–355.

    Article  CAS  Google Scholar 

  4. Min SH, Zhou XZ, Lu KP. The role of Pin1 in the development and treatment of cancer. Arch Pharm Res 2016;39:1609–1620.

    Article  CAS  Google Scholar 

  5. Hariharan N, Sussman MA. Pin1: a molecular orchestrator in the heart. Trends Cardiovasc Med 2014;24:256–262.

    Article  CAS  Google Scholar 

  6. Bartek J, Lukas J. DNA repair: Cyclin D1 multitasks. Nature 2011;474:171–172.

    Article  CAS  Google Scholar 

  7. Kruiswijk F, Hasenfuss SC, Sivapatham R, Baar MP, Putavet D, Naipal KAT, et al. Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. Oncogene 2016;35:2166–2177.

    Article  CAS  Google Scholar 

  8. Jin J, Zhang Y, Li Y, Zhang H, Li H, Yuan X, et al. RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells. Neoplasma 2013;60:92–100.

    Article  CAS  Google Scholar 

  9. Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, Fujimori F, et al. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci U S A 2002;99:1335–1340.

    Article  CAS  Google Scholar 

  10. Xu T, Zhang H, Park SS, Venneti S, Kuick R, Ha K, et al. Loss of Pin1 suppresses hedgehog-driven medulloblastoma tumorigenesis. Neoplasia 2017;19:216–225.

    Article  CAS  Google Scholar 

  11. Nakatsu Y, Matsunaga Y, Ueda K, Yamamotoya T, Inoue Y, Inoue MK, et al. Development of Pin1 Inhibitors and their potential as therapeutic agents. Curr Med Chem 2020;27:3314–3329.

    Article  CAS  Google Scholar 

  12. Chao SH, Greenleaf AL, Price DH. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. Nucleic Acids Res 2001;29:767–773.

    Article  CAS  Google Scholar 

  13. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010;75:1–18.

    Article  CAS  Google Scholar 

  14. Karki N, Aggarwal S, Laine RA, Greenway F, Losso JN. Cytotoxicity of juglone and thymoquinone against pancreatic cancer cells. Chem Biol Interact 2020;327:109142.

    Article  CAS  Google Scholar 

  15. Seetha A, Devaraj H, Sudhandiran G. Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol 2020;34:e22433.

    Article  CAS  Google Scholar 

  16. Xiao Y, Ming X, Xu J. Inhibition of human leukemia cells growth by juglone is mediated via autophagy induction, endogenous ROS production, and inhibition of cell migration and invasion. J Buon 2020;25:1600–1606.

    PubMed  Google Scholar 

  17. Zhao XY, Zhu WH, Zhang RW, Zhang M, Zhao JR, Hou JC, et al. Targeted juglone blocks the invasion and metastasis of HPV-positive cervical cancer cells. J Pharmacol Sci 2019;140:211–217.

    Article  CAS  Google Scholar 

  18. Li Z, Liu X, Li M, Chai JX, He S, Wu JF, et al. Juglone potentiates BRAF inhibitor-induced apoptosis in melanoma through reactive oxygen species and the p38p53 pathway. Mol Med Rep 2020;22:566–574.

    Article  CAS  Google Scholar 

  19. Liu X, Chen Y, Zhang Y, Du J, Lv YB, Mo SM, et al. Juglone potentiates TRAIL-induced apoptosis in human melanoma cells via activating the ROSp38p53 pathway. Mol Med Rep 2017;16:9645–9651.

    Article  Google Scholar 

  20. Kapadia CH, Perry JL, Tian S, Luft JC, DeSimone JM. Nanoparticulate immunotherapy for cancer. J Control Release 2015;219:167–180.

    Article  CAS  Google Scholar 

  21. Vieira DB, Gamarra LF. Advances in the use of nanocarriers for cancer diagnosis and treatment. Einstein (Sao Paulo) 2016;14:99–103.

    Article  Google Scholar 

  22. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007;59:718–728.

    Article  CAS  Google Scholar 

  23. Aithal BK, Sunil Kumar MR, Rao BN, Upadhya R, Prabhu V, Shavi G, et al. Evaluation of pharmacokinetic, biodistribution, pharmacodynamic, and toxicity profile of free juglone and its sterically stabilized liposomes. J Pharm Sci 2011;100:3517–3528.

    Article  CAS  Google Scholar 

  24. Huang KX, Wang XY, Shen YT, Li X. Study on targeting capacity of Juglone folate modified self-microemulsion in vivo and in vitro. Chin Hosp Pharm J (Chin) 2016;36:285–289.

    Google Scholar 

  25. Arasoglu T, Derman S, Mansuroglu B, Yelkenci G, Kocyigit B, Gumus B, et al. Synthesis, characterization and antibacterial activity of juglone encapsulated PLGA nanoparticles. J Appl Microbiol 2017;123:1407–1419.

    Article  CAS  Google Scholar 

  26. Wang H, Yu J, Lu X, He X. Nanoparticle systems reduce systemic toxicity in cancer treatment. Nanomedicine (Lond) 2016;11:103–106.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210008, China

    Wu-heng Yue, Rui Mei & Zheng-yun Zou

  2. Department of Oncology, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, Jiangsu Province, 215499, China

    Wu-heng Yue

  3. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, 210008, China

    Lan-qun Qin, Juan Cai & Zheng-yun Zou

  4. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, 210008, China

    Han-qing Qian & Zheng-yun Zou

Authors
  1. Wu-heng Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lan-qun Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rui Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Han-qing Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zheng-yun Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Yue WH and Zou ZY conceived the idea and designed the experiments. Yue WH and Qin LQ performed the experiments and interpreted the experimental results. Cai J, Mei R and Qian HQ participated in the study design and data analysis. Yue WH, Qin LQ and Zou ZY wrote the manuscript. All authors read and approved the current version of the manuscript.

Corresponding author

Correspondence to Zheng-yun Zou.

Additional information

Conflict of Interests

The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

Supported by the National Natural Science Foundation of China (Nos. 81872484 and 82073365) and the Social Development Fund of Jiangsu Province, China (No. BE2019605)

Supplementary material to

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yue, Wh., Qin, Lq., Cai, J. et al. Jug-PLGA-NPs, a New Form of Juglone with Enhanced Efficiency and Reduced Toxicity on Melanoma. Chin. J. Integr. Med. 28, 909–917 (2022). https://doi.org/10.1007/s11655-021-3461-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-021-3461-y

Keywords

Search

Navigation